




Welcome to the  
Imricor Annual Meeting

Wednesday, 13 May 2020 (AEST)  
Tuesday, 12 May 2020 (CDT)



## Please submit questions at any time throughout the meeting

- When the question function is available, the Q&A icon will appear at the top of the app.



- To send in a question, simply click in the 'Ask a question' box, type your question and then press the send arrow
- Your question will be sent immediately for review




# Voting online at the virtual meeting

- When the poll is open, the vote will be accessible by selecting the voting icon at the top of the screen



- To vote simply select the direction in which you would like to cast your vote, the selected option will change colour.
- There is no submit or send button, your selection is automatically recorded.





# Imricor's Board of Directors



Steve Wedan  
President and CEO,  
and Chair



Mark Tibbles  
Non-executive Director



Doris Engibous  
Non-executive Director



Peter McGregor  
Non-executive Director

# Chair's Address






## Commercial launch – first procedures at Dresden Heart Centre



*Dr. Christopher Piorkowski and Dr. Thomas Gaspar performing initial procedures at the Dresden Heart Centre*



# Active catheter imaging supporting lab adoption



## Active Catheter Imaging Provides

- Fluoroscopic-like MR imaging with easily identified catheter tip
- Increased speed for AFL ablations compared to active tracking and mapping
- Enhanced speed of adoption by allowing sites to get started without an active tracking and mapping system from Siemens
- Accelerated adoption for atrial flutter



## Lab roll out plans stalled by COVID-19

Key lab  
operational



- Dresden: Routine clinical procedures commenced in January

3 Sites with  
Signed Contracts



- Haga: Adv-MR installed
- UMC Ams: Adv-MR installed
- Leipzig: Adv-MR installed

7 Sites with  
Agreements in  
Final Stages



- In final stages of the sales process but cannot progress to execution of documentation until the COVID-19 crisis largely passes

14 Sites with  
Well-Progressed  
Discussions



- Well progressed and in the second half of the sales process

*Dresden and Leipzig established as training Centres of Excellence for sites that follow.*

*We have now formed three Imricor training and installation teams, therefore expanding our capacity to enable three sites per week to commence clinical procedures if required*



# Adapting to COVID-19 – launch of first online educational seminar

**imricor**  
Invites You  
to  
Experience the future of cardiac  
ablation while  
Drs Gaspar and Ulbrich  
will discuss the workflow of using  
the MR-Ablation catheters, the  
value of MR guided ablation, and  
the successes they have achieved  
with the ablation procedures.

THURSDAY | 2 | APRIL  
4:00pm (CET) Webinar  
Q & A to Follow

**REGISTER  
TODAY!**  
Use the link in the email to register!

YouTube AU Search

**imricor**

Imricor Webinar  
Hosted by: Dr. Thomas Gaspar and Dr. Stefan Ulbrich from the Dresden Heart Center

Imricor Webinar  
129 views • Apr 10, 2020

LIKE DISLIKE SHARE SAVE ...

**Imricor Medical Systems**  
23 subscribers

Experience the future of cardiac ablation while Dr. Thomas Gaspar and Dr. Stefan Ulbrich from the Dresden Heart Center discuss their successes performing cardiac ablation utilizing real-time MR imaging.

SHOW MORE

**SUBSCRIBE**



## Master purchasing agreement with Sana




### **Sana is the largest Group Purchasing Organisation in Germany**

- 600 cooperating hospitals and medical institutions across Germany and Switzerland
- 80 of these sites perform cardiac catheter ablations – potential Imricor customers
- Streamlines contract negotiations for new sites
- Facilitates access to 80 sites for sales and marketing – supporting our pipeline




# Product line expansion - improve gross margin, support expanding indications

## Diagnostic Catheter



- Development well advanced
- Scaled down Vision-MR ablation catheter aimed at faster approval process
- Regulatory strategy well advanced
- Top priority execution
- Aiming for Summer 2021 market release (pending approval)

## Steerable Sheath and Transseptal Needle



- Prototype phase
- Regulatory strategy being developed
- Fully staffed execution
- Aiming to be ready for clinical trials in 2021




# A phased approach to geographic expansion






# Growing the team to deliver growth opportunities and support product roll out

FTEs at IPO



FTEs Today





## Imricor's Board of Directors



Steve Wedan  
President and CEO,  
and Chair



Mark Tibbles  
Non-executive Director



Doris Engibous  
Non-executive Director



Peter McGregor  
Non-executive Director



Thank you for your support





# Disclaimer

The material contained in this presentation is intended to be general background information on Imricor Medical Systems Inc (“Imricor”) and its activities.

The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (US GAAP) and are denominated in US dollars.

This presentation may contain statements that constitute “forward-looking statements” within the meaning of Section 21E of the US Securities Exchange Act of 1934. Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding our intent, belief or current expectations with respect to our business and operations, market conditions, results of operations and financial condition.

We use words such as ‘will’, ‘may’, ‘expect’, ‘intend’, ‘seek’, ‘would’, ‘should’, ‘could’, ‘continue’, ‘plan’, ‘estimate’, ‘anticipate’, ‘believe’, ‘probability’, ‘risk’, ‘aim’, or other similar words to identify forward-looking statements. These forward-looking statements reflect our current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond our control, and have been made based upon management’s expectations and beliefs concerning future developments and their potential effect upon us. There can be no assurance that future developments will be in accordance with our expectations or that the effect of future developments on us will be those anticipated. Actual results could differ materially from those which we expect, depending on the outcome of various factors. Factors that may impact on the forward-looking statements made include, but are not limited to, those described in the section titled ‘Risk factors’ in Imricor’s prospectus dated 7 August 2019. When relying on forward-looking statements to make decisions with respect to us, investors and others should carefully consider such factors and other uncertainties and events. We are under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction.